Trial Information
DESTINY BREAST – RESPOND A multi-center, multi-country prospective observational study of patients initiating T-DXd in the first or second treatment line for HER2+, and HER2-low unresectable and/or metastatic breast cancer
Sponsor: AstraZeneca AB, 151 85 Södertälje, Sweden
Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at
877-664-7724
